News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,930 Results
Type
Article (39148)
Company Profile (283)
Press Release (648499)
Section
Business (203905)
Career Advice (1996)
Deals (35371)
Drug Delivery (89)
Drug Development (80847)
Employer Resources (168)
FDA (16100)
Job Trends (14810)
News (344649)
Policy (32453)
Tag
Academia (2531)
Alliances (49185)
Alzheimer's disease (1257)
Approvals (16051)
Artificial intelligence (144)
Bankruptcy (352)
Best Places to Work (11583)
Biotechnology (200)
Breast cancer (188)
Cancer (1365)
Cardiovascular disease (110)
Career advice (1664)
Cell therapy (281)
Clinical research (64693)
Collaboration (483)
Compensation (260)
COVID-19 (2541)
C-suite (108)
Data (1389)
Diabetes (172)
Diagnostics (6172)
Earnings (84892)
Employer resources (146)
Events (110012)
Executive appointments (394)
FDA (16769)
Funding (426)
Gene therapy (196)
GLP-1 (597)
Government (4333)
Healthcare (18693)
Infectious disease (2633)
Inflammatory bowel disease (111)
Interviews (309)
IPO (16339)
Job creations (3625)
Job search strategy (1418)
Layoffs (418)
Legal (7862)
Lung cancer (197)
Lymphoma (98)
Manufacturing (206)
Medical device (13211)
Medtech (13216)
Mergers & acquisitions (19192)
Metabolic disorders (452)
Neuroscience (1577)
NextGen Class of 2024 (6501)
Non-profit (4468)
Northern California (1694)
Obesity (258)
Opinion (183)
Patents (117)
People (56457)
Phase I (20119)
Phase II (28494)
Phase III (21237)
Pipeline (514)
Postmarket research (2560)
Preclinical (8545)
Radiopharmaceuticals (236)
Rare diseases (259)
Real estate (5890)
Regulatory (21666)
Research institute (2310)
Resumes & cover letters (349)
Southern California (1461)
Startups (3562)
United States (15142)
Vaccines (563)
Weight loss (181)
Date
Last 7 days (579)
Last 30 days (2250)
Last 365 days (35166)
2024 (35008)
2023 (40078)
2022 (51174)
2021 (55710)
2020 (54087)
2019 (46546)
2018 (35023)
2017 (32110)
2016 (31484)
2015 (37555)
2014 (31321)
2013 (26345)
2012 (28570)
2011 (29265)
2010 (27328)
Location
Africa (713)
Arizona (195)
Asia (37269)
Australia (6088)
California (3810)
Canada (1449)
China (304)
Colorado (171)
Connecticut (176)
Europe (79836)
Florida (533)
Georgia (135)
Illinois (384)
Indiana (224)
Maryland (626)
Massachusetts (2959)
Michigan (172)
Minnesota (290)
New Jersey (1100)
New York (1080)
North Carolina (742)
Northern California (1694)
Ohio (146)
Pennsylvania (923)
South America (1091)
Southern California (1461)
Texas (547)
Utah (108)
Washington State (399)
687,930 Results for "ev3 inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
Astellas Pharma Inc. and Seagen Inc. announced positive topline results from the Phase 3 EV-302 clinical trial for PADCEV® in combination with KEYTRUDA® versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer, a form of bladder cancer that has spread to surrounding organs or muscles, or other parts of the body.
September 22, 2023
·
24 min read
BioForest
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
Astellas Pharma Inc. and Seagen Inc. announced results from the Phase 3 EV-302 clinical trial for PADCEV® in combination with KEYTRUDA® versus chemotherapy.
October 22, 2023
·
27 min read
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
Press Releases
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.
December 20, 2024
·
2 min read
Press Releases
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
December 12, 2024
·
19 min read
Press Releases
BRIJ Medical, Inc. Awarded Breakthrough Technology Agreement in the Non-Invasive Skin Closure Category with Premier, Inc.
December 17, 2024
·
2 min read
Press Releases
CorMedix Inc. Added to Nasdaq Biotechnology Index
December 20, 2024
·
1 min read
Press Releases
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
November 26, 2024
·
9 min read
Press Releases
Scott Burger Appointed as CEO of AngioInsight, Inc.
December 17, 2024
·
2 min read
NurExone Biologic Announces Advancements in Extracellular Vesicles Functionality with Enhanced Potency and Cellular Uptake for potentially better drug delivery
NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”) is pleased to announce significant advancements in extracellular vesicles (EVs) functionality. Leveraging its proprietary and patented 3D-Flow production, the Company has achieved significantly enhanced EV functionality.
July 20, 2023
·
8 min read
1 of 68,793
Next
